This week in our news roundup: Cellectis’ shift toward in vivo gene editing comes with steep workforce cuts, while Sanofi and AstraZeneca add new technologies through deals. Elsewhere, respiratory developers plan a merger, Lithuania’s Biomatter raises funding and Zealand seeks partners for its rare-disease medicines.
The post